Gastric Electric Stimulators Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 272.71 Million |
| Market Size (2029) | USD 370.64 Million |
| CAGR (2024 - 2029) | 6.33 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Gastric Electric Stimulators Market Analysis
The Gastric Electric Stimulators Market size is estimated at USD 272.71 million in 2024, and is expected to reach USD 370.64 million by 2029, growing at a CAGR of 6.33% during the forecast period (2024-2029).
Major factors propelling the growth of the gastric electric stimulators market are the rising prevalence of gastroparesis and technological advancements in the market.
The prevalence of gastroparesis is increasing, particularly among diabetic patients, which is driving a significant demand for effective treatment options such as gastric electrical stimulation (GES). For instance, according to a report published by the Journal of Gastroenterology and Hepatology in January 2024, the global high prevalence of gastroparesis, which was estimated to affect 24.2 per 100,000 people in 2023, is driving the growth of the gastric electric stimulators market, as these devices offer an effective treatment option for managing symptoms in patients with delayed gastric emptying.
Similarly, according to a report published by the Clinical Gastroenterology and Hepatology in July 2022, the high prevalence of gastroparesis (GP), particularly among diabetic and female patients, along with increasing hospitalization and emergency department visit rates by 2- to 18-fold over two decades, is significantly driving the growth of the gastric electric stimulators market as healthcare providers seek effective long-term management solutions. Furthermore, the higher mortality rates associated with GP due to cardiovascular, respiratory, and malignancy complications underscore the urgent need for advanced treatments like gastric electric stimulators, thereby boosting market demand. This increasing demand is further propelled by the underdiagnosis in developing countries, suggesting a potentially larger market as awareness and diagnostic capabilities improve.
The growing patient pool underscores the need for innovative solutions in the market. The industry is experiencing a wave of technological advancements, particularly with the development of high-frequency stimulators. For instance, in April 2023, according to research conducted by the New York University, the development of the ingestible electroceutical capsule represents a novel approach to modulate gastric hormones like ghrelin through electrical stimulation, offering potential applications for treating various gastrointestinal and metabolic disorders. This innovation builds on existing gastric electrical stimulators, which have shown benefits in gastroparesis patients by providing a less invasive, ingestible option that leverages the body's systems to regulate hormone levels.
In conclusion, the growth of the gastric electric stimulators market is driven by the rising prevalence of gastroparesis and significant technological advancements, which underscore the urgent need for effective, innovative treatment solutions. However, high cost and regulatory issues are restraining the growth of the gastric electric stimulators market during the forecast period.
Gastric Electric Stimulators Market Trends
The Obesity Segment is Expected to Obtain Considerable Growth During the Forecast Period
Obesity rates are reaching alarming levels globally, posing a significant public health concern. For instance, according to a report published by the World Health Organization, in March 2024, over 390 million children and adolescents aged 5-19 years were overweight in 2022, including 160 million who were living with obesity. Moreover, the prevalence of obesity is observed to be growing at a high rate in developing countries. For instance, according to a report published by Lancet Health in May 2023, the prevalence of abdominal obesity in India was found to be 40% in women and 12% in men.
The report also suggested that 5–6 out of 10 women between the ages of 30-49 are abdominally obese. The obesity cases were observed to be higher among women (39.6%) than men (11.9%). Thus, traditional weight management strategies often yield limited long-term success, driving the search for innovative and minimally invasive approaches such as gastric electrical stimulation (GES) therapy. The growth of the GES market in the obesity segment is being propelled by several factors.
Moreover, initial results suggest that GES therapy can influence satiety and gastric emptying patterns, potentially leading to weight loss and improved metabolic health. For instance, according to a report published by the bioRxiv Journal in July 2023, the development of gastric electric stimulators, which effectively reduce food intake and minimize weight gain by activating gastric mechanoreceptors, represents a significant advancement in obesity treatment technology.
According to the same source, innovations in gastric electric stimulators, particularly relevant given that nearly 42% of American adults suffer from obesity, are expected to drive growth in the gastric electric stimulators market by offering a non-invasive, cost-effective alternative to traditional surgical and pharmacologic therapies. The research also indicates that GES may increase satiety hormones like cholecystokinin (CCK), resulting in feelings of fullness and reduced calorie intake.
Additionally, GES offers a minimally invasive alternative to traditional weight loss surgeries, with a shorter recovery time. For instance, according to a report published by the European Surgical Research in December 2023, minimally invasive procedures, such as vagal nerve therapy using devices, are driving the obesity segment of the gastric electric stimulators market by offering significant weight loss with fewer risks and complications compared to traditional bariatric surgeries. The study also highlighted that with up to 26% excess weight loss at 12 months and a well-tolerated safety profile, these procedures appeal to patients seeking effective weight management without permanent anatomical alterations, thus expanding the market reach and adoption. This less invasive approach may appeal to patients seeking a more conservative method of weight management, thus further driving interest and growth in the GES market.
In conclusion, the rising prevalence of obesity globally and the search for effective, minimally invasive treatments are propelling the growth of the gastric electrical stimulation market, offering promising advancements in weight management and metabolic health.
North America is Expected to Grow During the Forecast Period
North America has a well-established healthcare system with a high concentration of advanced medical facilities, research institutes, and a large pool of qualified medical professionals. Major factors such as the growing obesity rates, high awareness and prevalence of gastroparesis, and focus on minimally invasive procedures are propelling the North American gastric electric stimulators market.
The rising rates of obesity in North America, coupled with limited regulatory approval for gastric electrical stimulation (GES) in obesity management, drive ongoing research and development efforts to explore this application. For instance, according to a report published by the World Obesity Federation in January 2024, the United States ranks 10th globally for obesity. This alarming rise in obesity cases in the country is expected to drive significant growth in the North American gastric electric stimulators market.
Moreover, according to a report published by the Centers for Disease Control and Prevention (CDC) in September 2023, in 2022, the prevalence of adult obesity will be 35%. The adult obesity prevalence rate has risen by 35% in the last ten years. This highly rising prevalence rate of obesity is expected to increase the demand for anti-obesity drugs in the country. This focus positions North America as a potential leader for future growth in the GES segment.
Additionally, the region benefits from heightened public awareness of gastroparesis, bolstered by public awareness campaigns and well-established diagnostic pathways. For instance, in Canada, August is considered as an awareness month for gastroparesis since 2022. This increased awareness leads to earlier diagnosis and potentially accelerates the adoption of GES therapy as a treatment option.
Furthermore, the minimally invasive nature of GES therapy aligns with the growing preference for such procedures within the North American healthcare system. This preference facilitates faster patient recovery and can potentially reduce overall healthcare costs.
In conclusion, the North American gastric electric stimulators market is poised for growth driven by rising obesity rates, increasing awareness of gastroparesis, and a preference for minimally invasive medical procedures.
Gastric Electric Stimulators Industry Overview
The gastric electric stimulators market is fragmented. The use of gastric electric stimulators has become increasingly prevalent, with a number of global players focusing on differentiating themselves in a highly competitive space. Furthermore, there has been a recent influx of new entrants into the market who are rapidly gaining traction. Overall, it is expected that competitive rivalry within the industry will remain high during the forecast period.
Some of the major players in the gastric electric stimulators market are Changzhou Ruishen Medical Equipment Co. Ltd, Chentao Medical Equipment, Cigna HealthCare, Medtronic Inc., and ReShape Lifesciences Inc.
Gastric Electric Stimulators Market Leaders
-
Medtronic Inc.
-
ReShape Lifesciences, Inc.
-
Cigna HealthCare
-
Chentao Medical Equipment
-
Changzhou Ruishen Medical Equipment Co. Ltd.
*Disclaimer: Major Players sorted in no particular order
Gastric Electric Stimulators Market News
- March 2024: Medtronic entered a strategic alliance with Google to enhance gastric electrical stimulators using artificial intelligence (AI) technology. This collaboration aims to develop an advanced stimulator capable of dynamically adjusting to individual patient requirements. By leveraging AI capabilities, the partners intend to revolutionize treatment efficacy and personalization in this field, potentially setting new standards for medical device innovation and patient care.
- December 2023: The Food and Drug Administration (FDA) granted conditional use to Enterra Medical’s implantable electrical stimulation device for the management of symptoms associated with gastroparesis. The Enterra II system, specifically its component parts Enterra 37800 Neurostimulator and Enterra Therapy 4351-35 unipolar leads, is intended to relieve symptoms associated with gastroparesis, including nausea and vomiting.
Gastric Electric Stimulators Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Gastroparesis
4.2.2 Technological Advancements in the Gastric Electric Stimulators
4.3 Market Restraints
4.3.1 High Costs and Regulatory Issues
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD)
5.1 By Product Type
5.1.1 High-Frequency GES Devices
5.1.2 Low-Frequency GES Devices
5.2 By Application
5.2.1 Gastroparesis
5.2.2 Obesity
5.2.3 Refractory Nausea
5.2.4 Other Applications
5.3 By End User
5.3.1 Hospitals
5.3.2 Outpatient Centers
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Changzhou Ruishen Medical Equipment Co. Ltd
6.1.2 Chentao Medical Equipment
6.1.3 Cigna HealthCare
6.1.4 Medtronic Inc.
6.1.5 ReShape Lifesciences Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Gastric Electric Stimulators Industry Segmentation
As per the scope of the report, gastric electric stimulators are medical devices designed to deliver electrical impulses to the stomach to modulate gastric motility and address obesity and related gastrointestinal disorders. These devices are increasingly recognized for their potential to enhance patient outcomes by improving weight management and metabolic function.
The gastric electric stimulators market is segmented by product type, application, end user, and geography. By product type, the market is segmented into high-frequency GES devices and low-frequency GES devices. By application, the market is segmented into gastroparesis, obesity, refractory nausea, and other applications. Other applications include metabolic syndrome management and functional dyspepsia. By end user, the market is segmented into hospitals, outpatient centers, and other end users. Other end users include research institutions and academic centers. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market sizing and forecasts were made on the basis of value (USD).
| By Product Type | |
| High-Frequency GES Devices | |
| Low-Frequency GES Devices |
| By Application | |
| Gastroparesis | |
| Obesity | |
| Refractory Nausea | |
| Other Applications |
| By End User | |
| Hospitals | |
| Outpatient Centers | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Gastric Electric Stimulators Market Research FAQs
How big is the Gastric Electric Stimulators Market?
The Gastric Electric Stimulators Market size is expected to reach USD 272.71 million in 2024 and grow at a CAGR of 6.33% to reach USD 370.64 million by 2029.
What is the current Gastric Electric Stimulators Market size?
In 2024, the Gastric Electric Stimulators Market size is expected to reach USD 272.71 million.
Who are the key players in Gastric Electric Stimulators Market?
Medtronic Inc., ReShape Lifesciences, Inc., Cigna HealthCare, Chentao Medical Equipment and Changzhou Ruishen Medical Equipment Co. Ltd. are the major companies operating in the Gastric Electric Stimulators Market.
Which is the fastest growing region in Gastric Electric Stimulators Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Gastric Electric Stimulators Market?
In 2024, the North America accounts for the largest market share in Gastric Electric Stimulators Market.
What years does this Gastric Electric Stimulators Market cover, and what was the market size in 2023?
In 2023, the Gastric Electric Stimulators Market size was estimated at USD 255.45 million. The report covers the Gastric Electric Stimulators Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Gastric Electric Stimulators Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Gastric Electric Stimulators Industry Report
Statistics for the 2024 Gastric Electric Stimulators market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Gastric Electric Stimulators analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
